A new multi-drug combination therapy for pancreatic cancer is inching toward clinical trials in humans, according to University of Cincinnati researchers.
The drug compound, called SapC-DOPS, combines chemotherapy with targeted therapy and is capable of killing the cells that cause a number of cancers, including pancreatic cancer, which is notoriously difficult to treat.
"Based on pre-clinical studies, it has the potential to improve pancreatic cancer treatment," Xiaoyang Qi, PhD, a professor of hematology oncology at the University of Cincinnati College of Medicine and member of the UC Cancer Center. Qi is a lead author on the study which was published in the academic journal Molecular Therapy.
Read the full story.
Read the UC news release.
The Cincinnati Enquirer also covered this research.
Featured photo of pancreatic cancer cells courtesy of National Institutes of Health. Credit/Min Yu/Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC